<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35765222</PMID><DateCompleted><Year>2022</Year><Month>09</Month><Day>20</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>31</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-4598</ISSN><JournalIssue CitedMedium="Internet"><Volume>66</Volume><Issue>4</Issue><PubDate><Year>2022</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Muscle &amp; nerve</Title><ISOAbbreviation>Muscle Nerve</ISOAbbreviation></Journal><ArticleTitle>An expanded access protocol of RT001 in amyotrophic lateral sclerosis-Initial experience with a lipid peroxidation inhibitor.</ArticleTitle><Pagination><StartPage>421</StartPage><EndPage>425</EndPage><MedlinePgn>421-425</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/mus.27672</ELocationID><Abstract><AbstractText Label="INTRODUCTION/AIMS">Lipid peroxidation is thought to play a biologically important role in motor neuron death in amyotrophic lateral sclerosis (ALS). 11,11 Di-deuterated linoleic ethyl ester (RT001) prevents lipid peroxidation in cellular and mitochondrial membranes. Herein we report on the use of RT001 under expanded access (EA).</AbstractText><AbstractText Label="METHODS">We provided RT001 to patients with ALS via EA at a single site. The starting dose was 2.88&#x2009;g/day, which was increased to to 8.64&#x2009;g/day as tolerated. Participants were not eligible for alternative clinical trials. Participants were followed for adverse events and pharmacokinetic (PK) parameters were measured approximately 3&#xa0;months after RT001 initiation.</AbstractText><AbstractText Label="RESULTS">Sixteen participants received RT001 (5.6&#x2009;&#xb1;&#x2009;1.6 g/day; dose range, 1.92 to 8.64&#x2009;g/day) for a mean period of 10.8&#x2009;&#xb1;&#x2009;7.1&#xa0;months. After 3&#xa0;months of treatment, PK studies showed that RT001 was absorbed, metabolized, and incorporated into red blood cell membranes at concentrations expected to be therapeutic based on in vitro models. The most common adverse events were gastrointestinal, including diarrhea, which occurred in 25% of the participants, and were considered possibly related to RT001. One participant (6%) discontinued due to an adverse event. Ten serious adverse events occurred: these events were recognized complications of ALS and none were attributed to treatment with RT001.</AbstractText><AbstractText Label="DISCUSSION">RT001 was administered safely to a small group of people living with ALS in the context of an EA protocol. Currently, there is an ongoing randomized, double-blind, controlled study of RT001 in ALS.</AbstractText><CopyrightInformation>&#xa9; 2022 The Authors. Muscle &amp; Nerve published by Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yerton</LastName><ForeName>Megan</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Sean M. Healey and AMG Center for ALS &amp; the Neurological Clinical Research Institute, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Winter</LastName><ForeName>Allison</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Sean M. Healey and AMG Center for ALS &amp; the Neurological Clinical Research Institute, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kostov</LastName><ForeName>Anthony</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Sean M. Healey and AMG Center for ALS &amp; the Neurological Clinical Research Institute, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lieberman</LastName><ForeName>Cassandra</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Sean M. Healey and AMG Center for ALS &amp; the Neurological Clinical Research Institute, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gelevski</LastName><ForeName>Dario</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Sean M. Healey and AMG Center for ALS &amp; the Neurological Clinical Research Institute, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weber</LastName><ForeName>Harli</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Sean M. Healey and AMG Center for ALS &amp; the Neurological Clinical Research Institute, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Doyle</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Sean M. Healey and AMG Center for ALS &amp; the Neurological Clinical Research Institute, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kane</LastName><ForeName>Geli</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Sean M. Healey and AMG Center for ALS &amp; the Neurological Clinical Research Institute, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Parikh</LastName><ForeName>Neil</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Sean M. Healey and AMG Center for ALS &amp; the Neurological Clinical Research Institute, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Burke</LastName><ForeName>Katherine M</ForeName><Initials>KM</Initials><Identifier Source="ORCID">0000-0002-5820-5880</Identifier><AffiliationInfo><Affiliation>Sean M. Healey and AMG Center for ALS &amp; the Neurological Clinical Research Institute, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rohrer</LastName><ForeName>Margot</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Sean M. Healey and AMG Center for ALS &amp; the Neurological Clinical Research Institute, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stirrat</LastName><ForeName>Taylor</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Sean M. Healey and AMG Center for ALS &amp; the Neurological Clinical Research Institute, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bruno</LastName><ForeName>Margaret</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Sean M. Healey and AMG Center for ALS &amp; the Neurological Clinical Research Institute, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hochman</LastName><ForeName>Alison</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Sean M. Healey and AMG Center for ALS &amp; the Neurological Clinical Research Institute, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Luppino</LastName><ForeName>Sarah</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Sean M. Healey and AMG Center for ALS &amp; the Neurological Clinical Research Institute, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scalia</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Sean M. Healey and AMG Center for ALS &amp; the Neurological Clinical Research Institute, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Skoniecki</LastName><ForeName>Debra</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Sean M. Healey and AMG Center for ALS &amp; the Neurological Clinical Research Institute, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>D'Agostino</LastName><ForeName>Derek</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Sean M. Healey and AMG Center for ALS &amp; the Neurological Clinical Research Institute, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sinani</LastName><ForeName>Ervin</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Sean M. Healey and AMG Center for ALS &amp; the Neurological Clinical Research Institute, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Hong</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Sean M. Healey and AMG Center for ALS &amp; the Neurological Clinical Research Institute, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sherman</LastName><ForeName>Alexander V</ForeName><Initials>AV</Initials><AffiliationInfo><Affiliation>Sean M. Healey and AMG Center for ALS &amp; the Neurological Clinical Research Institute, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Babu</LastName><ForeName>Suma</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Sean M. Healey and AMG Center for ALS &amp; the Neurological Clinical Research Institute, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Berry</LastName><ForeName>James D</ForeName><Initials>JD</Initials><Identifier Source="ORCID">0000-0003-0898-6081</Identifier><AffiliationInfo><Affiliation>Sean M. Healey and AMG Center for ALS &amp; the Neurological Clinical Research Institute, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Midei</LastName><ForeName>Mark G</ForeName><Initials>MG</Initials><AffiliationInfo><Affiliation>Retrotope, Los Altos, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Milner</LastName><ForeName>Peter G</ForeName><Initials>PG</Initials><AffiliationInfo><Affiliation>Retrotope, Los Altos, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cudkowicz</LastName><ForeName>Merit E</ForeName><Initials>ME</Initials><Identifier Source="ORCID">0000-0002-7075-1681</Identifier><AffiliationInfo><Affiliation>Sean M. Healey and AMG Center for ALS &amp; the Neurological Clinical Research Institute, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paganoni</LastName><ForeName>Sabrina</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-0505-1168</Identifier><AffiliationInfo><Affiliation>Sean M. Healey and AMG Center for ALS &amp; the Neurological Clinical Research Institute, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Spaulding Rehabilitation Hospital, Harvard Medical School, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D000078325">Clinical Trial Protocol</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>07</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Muscle Nerve</MedlineTA><NlmUniqueID>7803146</NlmUniqueID><ISSNLinking>0148-639X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004952">Esters</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005227">Fatty Acids</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008041">Linoleic Acids</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000634027">RT001</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C013584">lipid peroxidation inhibitor</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004952" MajorTopicYN="N">Esters</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005227" MajorTopicYN="N">Fatty Acids</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008041" MajorTopicYN="N">Linoleic Acids</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">RT001</Keyword><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">expanded access program</Keyword><Keyword MajorTopicYN="N">motor neuron disease</Keyword></KeywordList><CoiStatement>A. Sherman reports research grants from the ALS Association, ALS Finding a Cure, and the National Institutes for Health. S. Babu has received research funding from AANEM Foundation, American Academy of Neurology, ALS Association, Muscular Dystrophy Association, Biogen, Orion Pharma, Novartis, Medicinova, Ionis, and AI Therapeutics. J.D. Berry reports research grants from Biogen, MT Pharma of America, Alexion, Rapa Therapeutics, the ALS Association, the Muscular Dystrophy Association, ALS One, Tambourine, and ALS Finding a Cure, and reports personal consulting fees from Biogen, Clene Nanomedicine, MT Pharma of America, Janssen. M.E. Cudkowicz reports consulting for Cytokinetics, Transposon, Als Pharma, Immunity Pharma, Faze, Regeneron, AB Science, RRD, Lilly, Biogen, MTPC, Neurosense, and Locust Walk, and is on the board of directors at Praxis. M.G. Midei and P.G. Milner are employed by Retrotope. S. Paganoni reports research grants from Amylyx Therapeutics, Revalesio Corporation, UCB/Ra Pharma, Biohaven, Clene, Prilenia, Seelos, the ALS Association, the American Academy of Neurology, ALS Finding a Cure, the Salah Foundation, the Spastic Paraplegia Foundation, the Muscular Dystrophy Association, and Tambourine, and reports personal consulting fees from Orion, Medscape, and Cytokinetics. The remaining authors declare no potential conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>6</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>2</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>6</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>6</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>9</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>6</Month><Day>29</Day><Hour>1</Hour><Minute>23</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35765222</ArticleId><ArticleId IdType="pmc">PMC9796343</ArticleId><ArticleId IdType="doi">10.1002/mus.27672</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Matsuo T, Adachi&#x2010;Tominari K, Sano O, et al. Involvement of ferroptosis in human motor neuron cell death. Biochem Biophys Res Commun. 2021;566:24&#x2010;29.</Citation><ArticleIdList><ArticleId IdType="pubmed">34111668</ArticleId></ArticleIdList></Reference><Reference><Citation>Beckman JS, Carson M, Smith CD, Koppenol WH. ALS, SOD and peroxynitrite. Nature. 1993;364:584.</Citation><ArticleIdList><ArticleId IdType="pubmed">8350919</ArticleId></ArticleIdList></Reference><Reference><Citation>Itoh K, Wakabayashi N, Katoh Y, et al. Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino&#x2010;terminal Neh2 domain. Genes Dev. 1999;13:76&#x2010;86.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC316370</ArticleId><ArticleId IdType="pubmed">9887101</ArticleId></ArticleIdList></Reference><Reference><Citation>Shichiri M. The role of lipid peroxidation in neurological disorders. J Clin Biochem Nutr. 2014;54:151&#x2010;160.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4042144</ArticleId><ArticleId IdType="pubmed">24895477</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmitt F, Hussain G, Dupuis L, et al. A plural role for lipids in motor neuron diseases: energy, signaling and structure. Front Cell Neurosci. 2014;8:25.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3929843</ArticleId><ArticleId IdType="pubmed">24600344</ArticleId></ArticleIdList></Reference><Reference><Citation>Barrera G, Gentile F, Pizzimenti S, et al. Mitochondrial dysfunction in cancer and neurodegenerative diseases: spotlight on fatty acid oxidation and lipoperoxidation products. Antioxidants. 2016;5(1):7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4808756</ArticleId><ArticleId IdType="pubmed">26907355</ArticleId></ArticleIdList></Reference><Reference><Citation>Firsov AM, Fomich MA, Bekish AV, et al. Threshold protective effect of deuterated polyunsaturated fatty acids on peroxidation of lipid bilayers. FEBS J. 2019;286:2099&#x2010;2117.</Citation><ArticleIdList><ArticleId IdType="pubmed">30851224</ArticleId></ArticleIdList></Reference><Reference><Citation>Zesiewicz T, Heerinckx F, DeJager R, et al. Randomized, clinical trial of RT001: early signals of efficacy in Friedreich's ataxia. Mov Disord. 2018;33:1000&#x2010;1005.</Citation><ArticleIdList><ArticleId IdType="pubmed">29624723</ArticleId></ArticleIdList></Reference><Reference><Citation>Brenna JT, James G, Midei M, et al. Plasma and red blood cell membrane accretion and pharmacokinetics of RT001 (bis&#x2010;allylic 11, 11&#x2010;D2&#x2010;linoleic acid ethyl ester) during long term dosing in patients. J Pharm Sci. 2020;109:3496&#x2010;1503.</Citation><ArticleIdList><ArticleId IdType="pubmed">32871154</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>